Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Multiple Myeloma 145Lymphoma, Follicular 41Lymphoma, Large B-Cell, Diffuse 36Lymphoma, B-Cell, Marginal Zone 24Recurrence 17Lymphoma, Mantle-Cell 17Lymphoma 16Neoplasms, Plasma Cell 15Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 11Neoplasms 9Lymphoma, B-Cell 8Smoldering Multiple Myeloma 7Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, Plasma Cell 4Waldenstrom Macroglobulinemia 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Plasmacytoma 2Pancreatic Neoplasms 2Neuroblastoma 2Lymphoma, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Hematologic Diseases 2Urinary Bladder Neoplasms 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Lenalidomide × 1 year × Clear all
NCT05182957 2026-05-01

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
31 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

Phase 1/2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡